Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited
Key Takeaways
- Ozempic is FDA-approved for type 2 diabetes management and to reduce major cardiovascular events in adults with type 2 diabetes and cardiovascular disease.
- The active ingredient is semaglutide, a GLP-1 receptor agonist that helps the body release insulin, slow digestion, and reduce appetite.
- Ozempic is widely prescribed off-label for weight loss; the FDA-approved weight-loss form of semaglutide is sold under the brand name Wegovy.
- Common doses: 0.25 mg starter, 0.5 mg, 1 mg, and 2 mg per week, taken as a once-weekly subcutaneous injection.
- Major trials (SUSTAIN-6) showed a 26% reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients.
Direct answer (40-60 words)
Ozempic (semaglutide) is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease. It's also widely prescribed off-label for weight loss. The active ingredient is semaglutide, given as a once-weekly injection.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Quick definition: what Ozempic is
- FDA-approved uses for Ozempic
- How Ozempic works in the body
- Off-label use: weight loss
- Ozempic dosage overview
- Side effects and contraindications
- Ozempic vs Wegovy vs Rybelsus
- Who is and isn't a candidate for Ozempic
- Cost and access
- FAQ
- Sources
- Footer disclaimers
Quick definition: what Ozempic is
Ozempic is the brand name for semaglutide injection, manufactured by Novo Nordisk and approved by the FDA in December 2017. It belongs to a class of medications called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs.
Ozempic is delivered as a once-weekly subcutaneous injection using a multi-dose pen. The pen is dialed to one of several preset doses (0.25 mg, 0.5 mg, 1 mg, or 2 mg) and injected into the abdomen, thigh, or upper arm.
The same active ingredient (semaglutide) is sold under three other brand names by the same manufacturer: Wegovy (FDA-approved for chronic weight management), Rybelsus (an oral tablet form for type 2 diabetes), and most recently in some markets a low-dose form for cardiovascular outcomes in non-diabetic patients with obesity.
FDA-approved uses for Ozempic
Ozempic has three FDA-approved indications as of 2026:
1. Glycemic control in adults with type 2 diabetes. Ozempic is approved as an adjunct to diet and exercise to improve A1C and blood glucose levels in adults with type 2 diabetes. It can be used as monotherapy or in combination with metformin, sulfonylureas, insulin, or other diabetes medications. In the SUSTAIN clinical trial program, Ozempic produced average A1C reductions of 1.4 to 1.8 percentage points across doses (Sorli et al., Lancet Diabetes Endocrinol 2017).
2. Cardiovascular risk reduction in adults with type 2 diabetes and known cardiovascular disease. In January 2020, the FDA expanded the Ozempic label to include a reduction in the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with both type 2 diabetes and established cardiovascular disease. This expansion was based on the SUSTAIN-6 trial, which showed a 26% relative risk reduction over a median follow-up of 2.1 years (Marso et al., NEJM 2016).
3. Reducing the risk of progression to chronic kidney disease in adults with type 2 diabetes. A more recent label expansion based on the FLOW trial (Perkovic et al., NEJM 2024) added kidney protection benefits for adults with type 2 diabetes and chronic kidney disease.
What Ozempic is not FDA-approved for: type 1 diabetes, weight management in non-diabetic adults (that's Wegovy's territory), or use in patients under 18.
How Ozempic works in the body
Semaglutide mimics a gut hormone called GLP-1 (glucagon-like peptide-1) that the small intestine releases in response to food. By activating the GLP-1 receptor, semaglutide produces several effects relevant to diabetes and weight:
1. Glucose-dependent insulin release. When blood sugar is elevated, semaglutide stimulates the pancreas to release insulin. When blood sugar is normal, it does not, which is why Ozempic alone rarely causes hypoglycemia (Drucker, Cell Metabolism 2018).
2. Suppression of glucagon. Glucagon is the hormone that tells the liver to release stored glucose. Semaglutide suppresses glucagon when blood sugar is high, lowering hepatic glucose output.
3. Slowed gastric emptying. Food stays in the stomach longer, leading to a slower rise in post-meal glucose and prolonged satiety.
4. Central appetite suppression. Semaglutide acts on GLP-1 receptors in the brain, particularly in the hypothalamus, reducing hunger and food reward signals. This is the dominant mechanism for weight loss effects.
5. Cardiovascular and renal protection. Mechanisms are still being characterized but include reduced inflammation, improved endothelial function, and direct effects on cardiac and renal cells (Marso et al., NEJM 2016; Perkovic et al., NEJM 2024).
The half-life of semaglutide is approximately seven days, which is why it's dosed once weekly. The molecule is engineered to bind to albumin in the blood, slowing its clearance.
Off-label use: weight loss
The most-discussed use of Ozempic in popular culture is weight loss, but technically Ozempic is not FDA-approved for that purpose. The FDA-approved semaglutide product for chronic weight management is Wegovy, which uses the same active ingredient at higher doses (up to 2.4 mg weekly).
That said, Ozempic is widely prescribed off-label for weight loss, particularly for patients with obesity who don't have insurance coverage for Wegovy or who can't access it due to supply issues. Off-label prescribing is legal in the U.S. when a licensed provider determines it's appropriate for an individual patient.
Weight loss outcomes on Ozempic vary by dose:
| Dose | Average weight loss (52 weeks) |
|---|---|
| 0.5 mg/week | ~5% body weight |
| 1 mg/week | ~6 to 7% body weight |
| 2 mg/week | ~9 to 10% body weight |
For comparison, Wegovy at the full 2.4 mg/week dose produces an average 14.9% body weight loss over 68 weeks (Wilding et al., NEJM 2021).
The mechanism of weight loss is the same across both products: appetite suppression, slowed gastric emptying, and modulation of food reward in the brain. Higher doses produce larger effects.
Ozempic dosage overview
Ozempic is dosed once weekly, with titration to minimize side effects.
| Week | Weekly dose | Typical purpose |
|---|---|---|
| 1 to 4 | 0.25 mg | Starter dose, GI tolerability |
| 5 to 8 | 0.5 mg | Maintenance for many patients |
| 9 to 12 | 1 mg | If A1C target not yet reached |
| 13+ | 2 mg | Maximum dose, rarely needed for diabetes |
The injection can be given any day of the week, into the abdomen (avoiding 2 inches around the navel), the thigh, or the upper arm. Inject at the same time each week. If a dose is missed by less than 5 days, take it as soon as possible. If more than 5 days, skip and resume the next week's dose.
The Ozempic pen is stored refrigerated (36 to 46°F) before first use. After first use, it can be kept at room temperature (up to 86°F) for up to 56 days.
For more detailed dosing guidance, see our Ozempic dosage chart.
Side effects and contraindications
The most common side effects of Ozempic are gastrointestinal:
- Nausea (15 to 20% of patients in trials)
- Vomiting (5 to 10%)
- Diarrhea (8 to 13%)
- Constipation (5 to 7%)
- Abdominal pain (5 to 7%)
Most GI side effects are dose-dependent and improve within 4 to 8 weeks of starting or after each dose increase. Slower titration reduces severity for patients with sensitive stomachs.
Less common but more serious side effects include:
- Pancreatitis. Symptoms include severe upper abdominal pain that radiates to the back. Stop Ozempic and seek care.
- Gallbladder problems. Including gallstones and cholecystitis. Risk is higher in patients losing weight rapidly.
- Diabetic retinopathy complications. In patients with pre-existing retinopathy, rapid glucose lowering can temporarily worsen the condition.
- Acute kidney injury. Usually associated with severe dehydration from vomiting or diarrhea.
- Allergic reactions. Rare but possible. Rash, swelling, difficulty breathing.
Contraindications. Do not take Ozempic if you have:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
The MTC warning comes from rodent carcinogenicity studies in which semaglutide caused thyroid C-cell tumors. Whether this risk extends to humans is unclear, but the FDA labeling reflects the precautionary signal.
For patients with concerns about specific side effects, see Ozempic and acid reflux and Ozempic constipation guide.
Ozempic vs Wegovy vs Rybelsus
All three contain semaglutide. The differences come down to formulation, dose, and approved use.
| Feature | Ozempic | Wegovy | Rybelsus |
|---|---|---|---|
| Form | Injection (weekly) | Injection (weekly) | Oral tablet (daily) |
| Approved for | Type 2 diabetes, CV risk | Chronic weight management | Type 2 diabetes |
| Max dose | 2 mg/week | 2.4 mg/week | 14 mg/day |
| Typical body weight loss | 5 to 10% | 14 to 16% | 3 to 5% |
| Approved age | 18+ | 12+ for adolescents with obesity | 18+ |
The same molecule produces different effects at different doses and through different delivery routes. Oral semaglutide (Rybelsus) has lower bioavailability than injected forms, which is why daily dosing is needed and the maximum effect is more modest.
Who is and isn't a candidate for Ozempic
Generally appropriate candidates:
- Adults with type 2 diabetes seeking better A1C control
- Adults with type 2 diabetes and established cardiovascular disease (where the cardiovascular risk reduction indication applies)
- Adults with type 2 diabetes and chronic kidney disease (where the renal protection indication applies)
- Adults with obesity, where off-label prescribing is clinically appropriate, especially when Wegovy is unavailable
Not appropriate or requires careful evaluation:
- Children under 18 (no FDA approval)
- Patients with type 1 diabetes
- Patients with personal or family history of medullary thyroid carcinoma
- Patients with severe gastroparesis (Ozempic worsens delayed gastric emptying)
- Pregnant or breastfeeding women (data is limited; generally avoided)
- Patients with a history of pancreatitis (relative contraindication)
- Patients with severe gastrointestinal disease
A licensed provider evaluates eligibility based on medical history, current medications, and treatment goals. For more on the eligibility process, see our GLP-1 medical eligibility guide.
Cost and access
Ozempic's list price is approximately $1,000 per month without insurance, though actual out-of-pocket cost varies widely depending on insurance coverage, manufacturer savings cards, and pharmacy choice.
For patients with type 2 diabetes, most commercial insurance plans cover Ozempic with a copay (often $25 to $100 per month). Medicare Part D coverage exists but with prior authorization. Medicaid coverage varies state-by-state.
For off-label weight-loss prescribing, insurance coverage is rare. Most patients pay full retail or use compounded semaglutide, which is typically less expensive but is not FDA-approved.
Manufacturer savings programs (the Novo Nordisk savings card) reduce the copay to as low as $25 per month for eligible insured patients. Eligibility requires commercial insurance and a type 2 diabetes diagnosis.
For patients without coverage, telehealth platforms offering compounded semaglutide can be a more affordable path. Note that compounded semaglutide is not the same as Ozempic; it's a different product prepared by a state-licensed compounding pharmacy. See why compounded semaglutide is sometimes red for more on the differences.
FAQ
What is Ozempic used for? Ozempic is FDA-approved to improve blood sugar control in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease, and to slow progression of chronic kidney disease in adults with type 2 diabetes. It is also widely prescribed off-label for weight loss.
Is Ozempic FDA-approved for weight loss? No. Ozempic is FDA-approved for type 2 diabetes and cardiovascular and renal indications. The FDA-approved version of semaglutide for weight management is Wegovy. Ozempic is sometimes prescribed off-label for weight loss, which is legal but not on its label.
How does Ozempic work? Ozempic is a GLP-1 receptor agonist. It mimics a gut hormone called GLP-1 to stimulate insulin release when blood sugar is high, slow gastric emptying, suppress glucagon, and reduce appetite. The result is better glucose control and, for many patients, weight loss.
How long does it take Ozempic to work? Blood sugar improvements appear within 1 to 2 weeks. Full A1C effect takes 8 to 12 weeks. Weight loss is gradual, typically 5 to 10% of body weight over 12 months at higher doses.
Can you take Ozempic if you don't have diabetes? A licensed provider can prescribe Ozempic off-label for non-diabetic patients, typically for weight loss, when clinically appropriate. The FDA-approved option for non-diabetic weight loss is Wegovy.
What's the most common side effect? Nausea is the most common side effect, reported by 15 to 20% of patients in trials. It's usually mild to moderate and improves within 4 to 8 weeks of starting or after each dose increase.
How much weight do you lose on Ozempic? Average weight loss varies by dose: about 5% at 0.5 mg/week, 6 to 7% at 1 mg/week, and 9 to 10% at 2 mg/week over 52 weeks. Wegovy (semaglutide at 2.4 mg/week) produces about 14 to 16% loss.
Is Ozempic the same as Wegovy? Both contain semaglutide. Ozempic is approved for type 2 diabetes and cardiovascular and renal indications, with maximum dose 2 mg/week. Wegovy is approved for chronic weight management, with maximum dose 2.4 mg/week. The active molecule is identical.
How long do you stay on Ozempic? Type 2 diabetes is a chronic condition; most patients stay on Ozempic indefinitely. For weight loss, stopping Ozempic typically leads to regain of most lost weight, so long-term use or a maintenance dose is often part of the plan.
Can I drink alcohol on Ozempic? Light to moderate drinking is generally compatible. Heavy or binge drinking raises the risk of low blood sugar (especially in patients also on insulin or sulfonylureas) and pancreatitis. Alcohol can worsen GI side effects.
What happens if I stop taking Ozempic? Blood sugar typically rises back toward baseline over weeks. Weight tends to be regained over months as appetite returns. The STEP 4 study showed substantial weight regain when semaglutide was stopped (Rubino et al., JAMA 2021).
Does Ozempic cause hypoglycemia? Ozempic alone rarely causes low blood sugar because it stimulates insulin release only when blood sugar is high. The risk increases when Ozempic is combined with insulin or sulfonylureas; doses of those medications are often reduced when Ozempic is added.
Sources
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834-1844.
- Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine. 2024.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018;27:740-756.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight maintenance (STEP 4). JAMA. 2021;325:1414-1425.
- Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
- FDA. Highlights of Prescribing Information for Ozempic (semaglutide) injection. Updated 2024.
- Aroda VR, et al. PIONEER 1: Randomized clinical trial comparing oral semaglutide with placebo. Diabetes Care. 2019.
- Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER-6). New England Journal of Medicine. 2019.
- American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →